An Ephemeral Review on Pulmonary Arterial Hypertension

Pulmonary arterial hypertension [PAH] is a rare and potentially fatal disease whose management is usually restricted to a few specialized centers. The crucial vascular modifications in pulmonary arterial hypertension are endothelial-cell proliferation, vasoconstriction, thrombosis and smooth-muscle cell. As patients don’t essentially board in the neighborhood to those centers, daily care and emergencies ought to be delegated to the primary and second lines. Reduced contractility of mycardium, decreased venous return and abnormal rate of exchange of gases leads to deprivation of oxygen to cell and death. Diagnosing and management of pulmonary arterial hypertension is critical. There is no cure for PAH. Modern developments regarding cell biology, molecular genetics and of idiopathic pulmonary arterial hypertension create new insights and therapeutic targets in the management. However, there are several treatment options that aim to reduce symptoms, improve the quality of life, and slow disease progression. This short review provides an outline of our therapeutic protocols supported out there information. Based on the analysis of the reasons for death in the PAH population, a review of the main emergencies is provided. Drugs include vasodilators, anticoagulants, antiplatelet agents, antiinflammatory therapies, and vascular-remodeling therapies. Most of the drugs have pleiotropic effects.